.
 
.

Preclinical Safety Evaluation of Biopharmaceutical

.
Redna cena: 214,34 €
Predvideni rok dobave: 14-21 dni
.
.
Količina:  
.
Strošek dostave je enoten za celo Slovenijo in znaša 2,95 €, ne glede na količino in vrsto kupljenih izdelkov.

Številni izdelki imajo oznako "brezplačna dostava", kar pomeni, da v prmeru nakupa takšnega izdelka poštnine ne boste plačali. 

Več o dostavi
Emka.si omogoča naslednje načine plačila:
  • z gotovino ob prevzemu (velja le za fizične osebe),
  • s plačilno oziroma kreditno kartico (Mastercard, Visa, ActivaMaestro, Activa, Diners, American Express),
  • s storitvijo Moneta (Mobitel in Simobil)
  • Plačilo po predračunu (pravne osebe)
  • Račun z odlogom plačila (za javna podjetja)
Več o plačilih

Pri vsakem izdelku je naveden predviden rok dostave. Glede na to katere izdelke izberete, se vam pri oddaji naročila prikaže tudi končni predviden datum dobave vašega pakete.

Večino izdelkov dostavljamo iz lastne zaloge, zato so naši dobavni roki zelo kratki.

Ko vam bomo poslali paket boste o tem obveščeni tudi po emailu. V emailu bo navedena številka vašega paketa ter povezava do Pošte Slovenije, kjer boste lahko preverili natančen status dostave.

Več o dostavi

To je spletna cena
Shrani v seznam želja
.

.

Opis

"The goal is to provide a comprehensive reference book for the preclinicaldiscovery and development scientist whose responsibilities span target identification, lead candidate selection, pharmacokinetics, pharmacology, and toxicology, and for regulatory scientists whose responsibilities include the evaluation of novel therapies."
—From the Afterword by Anthony D. Dayan

Proper preclinical safety evaluation can improve the predictive value, lessen the time and cost of launching new biopharmaceuticals, and speed potentially lifesaving drugs to market. This guide covers topics ranging from lead candidate selection to establishing proof of concept and toxicity testing to the selection of the first human doses. With chapters contributed by experts in their specific areas, Preclinical Safety Evaluation of Biopharmaceuticals: A Science-Based Approach to Facilitating Clinical Trials:
  • Includes an overview of biopharmaceuticals with information on regulation and methods of production
  • Discusses the principles of ICH S6 and their implementation in the U.S., Europe, and Japan
  • Covers current practices in preclinical development and includes a comparison of safety assessments for small molecules with those for biopharmaceuticals
  • Addresses all aspects of the preclinical evaluation process, including: the selection of relevant species; safety/toxicity endpoints; specific considerations based upon class; and practical considerations in the design, implementation, and analysis of biopharmaceuticals
  • Covers transitioning from preclinical development to clinical trials
This is a hands-on, straightforward reference for professionals involved in preclinical drug development, including scientists, toxicologists, project managers, consultants, and regulatory personnel.
.
.
.

O avtorju - Joy A. Cavagnaro

Obvestite me o novi knjigi tega avtorja

Želite, da vas po elektronski pošti obvestimo, ko izide nova knjiga ali ponatis katere od knjig tega avtorja?

DA - obveščajte me o novostih avtorja
.
.
.
.

Podrobnosti o izdelku

Mnenja kupcev

  0  ocen:
5 zvezdice
0%
(0)
4 zvezdice
0%
(0)
3 zvezdice
0%
(0)
2 zvezdice
0%
(0)
1 zvezdica
0%
(0)
Povprečna ocena kupcev:
Ocena kupcev: 0
(0 ocen uporabnikov )
.
Ocenite izdelek s klikom na zvezdice:
 
.
.
.
.
.

Oznake kupcev o tem izdelku

Kliknite na posamezno oznako za prikaz vseh izdelkov označenih s to oznako:

Dodaj oznako:

Dodaj
.